Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Declines By 21.4%

Xenetic Biosciences Inc (NASDAQ:XBIO) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 7,700 shares, a decrease of 21.4% from the January 15th total of 9,800 shares. Based on an average trading volume of 19,200 shares, the short-interest ratio is presently 0.4 days. Currently, 0.6% of the company’s shares are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Xenetic Biosciences stock. LGT Group Foundation acquired a new stake in Xenetic Biosciences Inc (NASDAQ:XBIO) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned approximately 0.71% of Xenetic Biosciences at the end of the most recent quarter. Hedge funds and other institutional investors own 15.12% of the company’s stock.

Xenetic Biosciences Stock Performance

Shares of Xenetic Biosciences stock opened at $4.11 on Friday. The firm has a market capitalization of $6.33 million, a price-to-earnings ratio of -1.54 and a beta of 2.23. Xenetic Biosciences has a fifty-two week low of $2.78 and a fifty-two week high of $5.20. The stock has a 50 day moving average of $4.15 and a 200 day moving average of $4.00.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.14). Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. The firm had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.75 million. Analysts forecast that Xenetic Biosciences will post -1.01 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a research report on Thursday, December 5th.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.